AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00475020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days
Study NCT00475020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m\^2 by vein daily over 1 hour x 4 days
Study NCT00475020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
Study NCT03267056 — intervention group
Intervention type: DEVICE
Intervention: drug eluting balloon catheter (trade name: Orchid)
Description: use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
Study NCT00586521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kogenate (BAY14-2222)
Description: One group two treatment schedules, first on-demand then switch to prophylaxis
Study NCT02583542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
Study NCT02583542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
Study NCT02311023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Study NCT01600495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental TENS
Description: Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
Study NCT01463280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tumescent lidocaine infiltration
Description: Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
Study NCT05100758 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active Hexoses Correlated Compound
Description: Active Hexose Correlated Compound was isolated from basidiomycetes which comprise polysaccharides and amino acids.
Study NCT04200508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted gown and gloves use
Description: Gown and glove use for high risk care activities in high risk residents
Study NCT02668016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20mg tablets taken orally once daily for one month.
Study NCT02668016 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally once daily for one month
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 High dose
Description: JNJ-64281802 high dose will be administered orally.
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Medium dose
Description: JNJ-64281802 medium dose will be administered orally.
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Low dose
Description: JNJ-64281802 low dose will be administered orally.
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Dosing Regimen X
Description: JNJ-64281802 dosing regimen X will be administered orally.
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Dosing Regimen Y
Description: JNJ-64281802 dosing regimen Y will be administered orally.
Study NCT04480736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64281802 Dosing Regimen Z
Description: JNJ-64281802 dosing regimen Z will be administered orally.
Study NCT02106585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-251 or Placebo
Description: Subjects will receive JTT-251 or Placebo
Study NCT02260401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized report
Description: Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
Study NCT03021668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prevena Peel & Place Dressing
Description: Prevena Peel \& Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
Study NCT03021668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Closure of the Surgical Incision
Description: This would involve standard closure of the incision site
Study NCT02486679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostin (PGE2) tablets
Study NCT02486679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Study NCT02976142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoimmunotherapy
Study NCT01563848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
Study NCT01563848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of loop recorder
Description: The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events
Study NCT01563848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
Study NCT00480792 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GenHevac B Pasteur
Description: Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
Study NCT00480792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenHevac B Pasteur
Description: Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
Study NCT00480792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenHevac B Pasteur
Description: GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
Study NCT03524547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J shaped stylet used for endotracheal intubation
Description: After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
Study NCT03524547 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 60-degrees stylet used for endotracheal intubation
Description: After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
Study NCT03788421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIGASURE
Description: Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
Study NCT00968981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Three times weekly oral repeating dose
Study NCT00968981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Once weekly oral repeating dose
Study NCT00829140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00829140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg BID
Study NCT03861299 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Description: Awake craniotomy
Study NCT03861299 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy under general anesthesia
Description: Craniotomy under general anesthesia
Study NCT00184717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
Study NCT00184717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
Study NCT02780141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral
Study NCT04480671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Level III support procedure
Description: A level III support procedure is aimed at repairing the distal support of the vagina with either a posterior colporrhaphy and/or a perineorrhaphy.
Study NCT04480671 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally Invasive Sacrocolpopexy
Description: All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.
Study NCT04480671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Sacrocolpopexy
Description: All study participants are planning with their surgeon a minimally invasive sacrocolpopexy (robotic or laparoscopic) to repair pelvic organ prolapse.
Study NCT04480671 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transperineal ultrasound of the Pelvic Floor
Description: Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
Study NCT04480671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal ultrasound of the Pelvic Floor
Description: Subjects from either arm will be invited to participate in this exploratory arm of the study. If they choose to participate, they will have a preoperative ultrasound performed and an ultrasound performed at the time of their 6 month visit.
Study NCT03494231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX06
Description: recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
Study NCT01071980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck
Description: Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
Study NCT01185184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Single doses separated by a minimum of 72 hour washout between treatments
Study NCT02339480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
Study NCT02667964 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: spiroergometry
Description: Spiroergometry on a bicycle ergometer
Study NCT01858116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]ABY-025
Description: Intravenous injection followed by PET imaging
Study NCT03937440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block with 'rocunium®'
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
Study NCT03425448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin hemodialysis catheter lock solution
Study NCT03425448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neutrolin
Description: Neutrolin hemodialysis catheter lock
Study NCT01309009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant oral solution
Description: Oral administration once daily for 7 days
Study NCT01309009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Nepadutant oral solution
Description: Oral administration once daily for 7 days
Study NCT01000753 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT03788421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamping and suturing
Description: Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
Study NCT03596099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mizkan rice vinegar with acetic acid
Description: 200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
Study NCT00771225 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: fascial repair
Description: surgery to treat genital prolapse with fascia repair
Study NCT00771225 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: mesh repair
Description: surgery to genital prolapse with mesh
Study NCT03596099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mizkan rice vinegar without acetic acid
Description: 200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
Study NCT04618601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is >5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.
Study NCT01385358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopically Assisted Surgical Ablation
Description: Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
Study NCT01385358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
Study NCT00674089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: Vitamin A 50,000 IU
Study NCT00674089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin A Placebo
Study NCT02079064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Inhalational anesthetic
Study NCT02079064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Intravenous anesthetic that can be given by continuous infusion
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: : given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin
Description: Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth
Description: Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT02633930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
Study NCT05401643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xemio mobile application
Description: The study consists in a mHealth intervention provided through the Xemio mobile application for breast cancer survivors. This application is installed in the personal smartphones of the participants after they are randomized in the mHealth intervention group. The Xemio app components are symptom tracking, up-to-date calendar of events organized by patient's organizations, virtual talks with experts, articles regarding new information of the disease, physical activity tracking, and evidence-based information regarding symptoms, non-pharmacological treatments for side effects, and information about common drugs to treat breast cancer. The participants can freely use the Xemio mobile application for a total of 12 months.~The control group does not have access to the Xemio application for the duration of the study but they are offered access to it at the completion of the intervention. The participants of both arms continued to receive the usual care from their oncology teams.
Study NCT03245385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Halobetasol propionate 0.05% topical spray
Description: Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
Study NCT02932592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (i Pro 2 - Medtronic)
Description: This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
Study NCT03156322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mL epidural initiation volume (bupivacaine + fentanyl)
Description: 5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
Study NCT03156322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL epidural initiation volume (bupivacaine + fentanyl)
Description: 10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter